July, 2020

Telix Pharmaceuticals reports receipt of $11.4M Refundable R&D Tax Offset

Melbourne-based Telix Pharmaceuticals Ltd has reported during the week receipt of an $11.4M Refundable R&D Tax Offset in respect of activity conducted during the YE 31 December 2019. This would be one of the largest single-year Refundable offset receipts in the history of the R&D Tax Incentive and infers an R&D Expenditure of approximately $26M AUD. The underlying activity relates to the development of diagnostic and therapeutic products using molecularly targeted radiation. Receipt of a tax offset of this magnitude […]

Read More